Geron Details RYTELO Growth Plan, $220M-$240M 2026 Sales Guide and MF Trial Catalyst at Barclays Conference [Yahoo! Finance]
Geron Corporation (GERN)
Last geron corporation earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
geron.com/investors
Company Research
Source: Yahoo! Finance
targeting reduced operating expenses ($230M–$240M) and carrying about $400M in cash to support growth and international optionality. Early commercial traction : Management highlighted 9% demand growth in the most recent quarter, about 1,300 purchasing accounts (150 added recently) and ~30% of business in first- and second-line settings, with a focus on community adoption and physician education to manage treatment-related cytopenias. Myelofibrosis trial catalyst : The Phase 3 IMPACT MF trial is fully enrolled with overall survival as the primary endpoint and an interim analysis expected in the second half of the year, representing a potential near-term catalyst. Interested in Geron Corporation? Here are five stocks we like better. Geron Corporation: FDA Approval Fuels Stock Price Surge Executives from Geron (NASDAQ:GERN) outlined their commercial priorities for RYTELO (imetelstat) and provided updates on the company's pipeline and financial outlook during a discussion hosted
Show less
Read more
Impact Snapshot
Event Time:
GERN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GERN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GERN alerts
High impacting Geron Corporation news events
Weekly update
A roundup of the hottest topics
GERN
News
- Geron: Minimal Sales Growth But A Potential Run-Up Ahead [Seeking Alpha]Seeking Alpha
- Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Geron Corporation (GERN) Reports Q4 EPS of (5c) [Yahoo! Finance]Yahoo! Finance
- Geron Corporation (GERN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- How The Geron (GERN) Story Is Shifting After Target Cut And New Equity Plans [Yahoo! Finance]Yahoo! Finance
GERN
Earnings
- 2/25/26 - Miss
GERN
Sec Filings
- 3/3/26 - Form SCHEDULE
- 3/2/26 - Form S-3ASR
- 3/2/26 - Form 10-K
- GERN's page on the SEC website